PURPOSE: To evaluate single-agent activity of bevacizumab in patients with recurrent glioblastoma. PATIENTS AND METHODS: Patients with recurrent glioblastoma were treated with bevacizumab 10 mg/kg every 2 weeks. After tumor progression, patients were immediately treated with bevacizumab in combination with irinotecan 340 mg/m(2) or 125 mg/m(2) every 2 weeks, depending on use of enzyme-inducing antiepileptic drugs. Complete patient evaluations were repeated every 4 weeks. RESULTS: Forty-eight heavily pretreated patients were accrued to this study. Thromboembolic events (12.5%), hypertension (12.5%), hypophosphatemia (6%), and thrombocytopenia (6%) were the most common drug-associated adverse events. Six patients (12.5%) were removed from study for drug-associated toxicity (five thromboembolic events, one bowel perforation). Thirty-four patients (71%) and 17 patients (35%) achieved radiographic response based on Levin and Macdonald criteria, respectively. Median progression-free survival (PFS) was 16 weeks (95% CI, 12 to 26 weeks). The 6-month PFS was 29% (95% CI, 18% to 48%). The 6-month overall survival was 57% (95% CI, 44% to 75%). Median overall survival was 31 weeks (95% CI, 21 to 54 weeks). Early magnetic resonance imaging response (first 96 hours and 4 weeks) was predictive of long-term PFS, with the Levin criteria being more predictive than Macdonald criteria. Of 19 patients treated with bevacizumab plus irinotecan at progression, there were no objective radiographic responses. Eighteen patients (95%) experienced disease progression by the second cycle, and the median PFS was 30 days. CONCLUSION: We conclude that single-agent bevacizumab has significant biologic and antiglioma activity in patients with recurrent glioblastoma.
PURPOSE: To evaluate single-agent activity of bevacizumab in patients with recurrent glioblastoma. PATIENTS AND METHODS: Patients with recurrent glioblastoma were treated with bevacizumab 10 mg/kg every 2 weeks. After tumor progression, patients were immediately treated with bevacizumab in combination with irinotecan 340 mg/m(2) or 125 mg/m(2) every 2 weeks, depending on use of enzyme-inducing antiepileptic drugs. Complete patient evaluations were repeated every 4 weeks. RESULTS: Forty-eight heavily pretreated patients were accrued to this study. Thromboembolic events (12.5%), hypertension (12.5%), hypophosphatemia (6%), and thrombocytopenia (6%) were the most common drug-associated adverse events. Six patients (12.5%) were removed from study for drug-associated toxicity (five thromboembolic events, one bowel perforation). Thirty-four patients (71%) and 17 patients (35%) achieved radiographic response based on Levin and Macdonald criteria, respectively. Median progression-free survival (PFS) was 16 weeks (95% CI, 12 to 26 weeks). The 6-month PFS was 29% (95% CI, 18% to 48%). The 6-month overall survival was 57% (95% CI, 44% to 75%). Median overall survival was 31 weeks (95% CI, 21 to 54 weeks). Early magnetic resonance imaging response (first 96 hours and 4 weeks) was predictive of long-term PFS, with the Levin criteria being more predictive than Macdonald criteria. Of 19 patients treated with bevacizumab plus irinotecan at progression, there were no objective radiographic responses. Eighteen patients (95%) experienced disease progression by the second cycle, and the median PFS was 30 days. CONCLUSION: We conclude that single-agent bevacizumab has significant biologic and antiglioma activity in patients with recurrent glioblastoma.
Authors: E T Wong; K R Hess; M J Gleason; K A Jaeckle; A P Kyritsis; M D Prados; V A Levin; W K Yung Journal: J Clin Oncol Date: 1999-08 Impact factor: 44.544
Authors: D F Stefanik; W K Fellows; L R Rizkalla; W M Rizkalla; P P Stefanik; A B Deleo; W C Welch Journal: J Neurooncol Date: 2001-11 Impact factor: 4.130
Authors: M Maxwell; S P Naber; H J Wolfe; E T Hedley-Whyte; T Galanopoulos; J Neville-Golden; H N Antoniades Journal: Cancer Res Date: 1991-02-15 Impact factor: 12.701
Authors: Tracy T Batchelor; Mark R Gilbert; Jeffrey G Supko; Kathryn A Carson; Louis B Nabors; Stuart A Grossman; Glenn J Lesser; Tom Mikkelsen; Surasak Phuphanich Journal: Neuro Oncol Date: 2004-01 Impact factor: 12.300
Authors: Joon Oh Park; Soon Il Lee; Seo Young Song; Kihyun Kim; Won Seog Kim; Chul Won Jung; Young Suk Park; Young-Hyuk Im; Won Ki Kang; Mark Hong Lee; Kyung Soo Lee; Keunchil Park Journal: Jpn J Clin Oncol Date: 2003-10 Impact factor: 3.019
Authors: Tracy T Batchelor; Dan G Duda; Emmanuelle di Tomaso; Marek Ancukiewicz; Scott R Plotkin; Elizabeth Gerstner; April F Eichler; Jan Drappatz; Fred H Hochberg; Thomas Benner; David N Louis; Kenneth S Cohen; Houng Chea; Alexis Exarhopoulos; Jay S Loeffler; Marsha A Moses; Percy Ivy; A Gregory Sorensen; Patrick Y Wen; Rakesh K Jain Journal: J Clin Oncol Date: 2010-05-10 Impact factor: 44.544
Authors: Gerald S Falchook; Jennifer J Wheler; Aung Naing; Sarina A Piha-Paul; Siqing Fu; Apostolia M Tsimberidou; David S Hong; Filip Janku; Ralph Zinner; Yunfang Jiang; Mei Huang; Quan Lin; Kristin Parkhurst; Razelle Kurzrock Journal: Invest New Drugs Date: 2014-11-04 Impact factor: 3.850
Authors: Tracy T Batchelor; David A Reardon; John F de Groot; Wolfgang Wick; Michael Weller Journal: Clin Cancer Res Date: 2014-11-15 Impact factor: 12.531
Authors: Wolfgang Wick; Michael Weller; Markus Weiler; Tracy Batchelor; Alfred W K Yung; Michael Platten Journal: Neuro Oncol Date: 2011-06 Impact factor: 12.300
Authors: Peter S LaViolette; Alex D Cohen; Melissa A Prah; Scott D Rand; Jennifer Connelly; Mark G Malkin; Wade M Mueller; Kathleen M Schmainda Journal: Neuro Oncol Date: 2013-02-03 Impact factor: 12.300